Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;85(1):9-20.
doi: 10.1007/s00280-019-03950-y. Epub 2019 Sep 11.

Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development

Gesuino Angius  1 , Silverio Tomao  2 , Valeria Stati  3 , Patrizia Vici  4 , Vincenzo Bianco  5 , Federica Tomao  6
Affiliations
Review

Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development

Gesuino Angius et al. Cancer Chemother Pharmacol. 2020 Jan.

Abstract

Checkpoint kinases 1 and 2 (CHK1 and CHK2) are important multifunctional proteins of the kinase family. Their main function is to regulate DNA replication and DNA damage response. If a cell is exposed to exogenous damage to its DNA, CHK1/CHK2 stops the cell cycle to give time to the cellular mechanisms to repair DNA breakage and apoptosis too, if the damage is not repairable to activate programmed cell death. CHK1/CHK2 plays a crucial role in the repair of recombination-mediated double-stranded DNA breaks. The other important functions performed by these proteins are the beginning of DNA replication, the stabilization of replication forks, the resolution of replication stress and the coordination of mitosis, even in the absence of exogenous DNA damage. Prexasertib (LY2606368) is a small ATP-competitive selective inhibitor of CHK1 and CHK2. In preclinical studies, prexasertib in monotherapy has shown to induce DNA damage and tumor cells apoptosis. The preclinical data and early clinical studies advocate the use of prexasertib in solid tumors both in monotherapy and in combination with other drugs (antimetabolites, PARP inhibitors and platinum-based chemotherapy). The safety and the efficacy of combination therapies with prexasertib need to be better evaluated in ongoing clinical trials.

Keywords: Advanced squamous cell carcinoma (SCC); CHK inhibitors; CHK1; CHK2; Checkpoint kinase 1 and 2; LY2606368; Ovarian cancer; PARP inhibitors; Prexasertib.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources